Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of...

Full description

Bibliographic Details
Main Authors: Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:JTO Clinical and Research Reports
Subjects:
Entrectinib
Intracranial efficacy
NSCLC
ROS1 fusions
Treatment post-crizotinib
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432200056X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432200056X

Similar Items